Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HER-2 Positive Breast Cancer × Metformin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 21 Breast Neoplasms 18 Carcinoma, Non-Small-Cell Lung 11 Polycystic Ovary Syndrome 9 Colorectal Neoplasms 9 Lung Neoplasms 8 Pancreatic Neoplasms 6 Endometrial Neoplasms 6 Neoplasms 5 Glioblastoma 5 Lymphoma, Large B-Cell, Diffuse 4 Adenocarcinoma of Lung 4 Adenocarcinoma 4 Rectal Neoplasms 3 Melanoma 3 Leukoplakia, Oral 3 Insulin Resistance 3 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Neoplasm Metastasis 2 Liver Neoplasms 2 Leukemia, Myeloid, Acute 2 Hyperandrogenism 2 Esophageal Neoplasms 2 Erythroplasia 2 Diabetes Mellitus 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Hepatocellular 2 Brain Neoplasms 2

Interventions

liposomal doxorubicin 1 Trastuzumab 1 Metformin 1 Doxorubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02488564 2025-02-03

met-HEReMYTA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Completed

HER-2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡